시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
비호지킨림프종 치료제 시장 규모, 점유율, 성장 분석 : 치료 종류별, 약물 종류별, 투여 경로별, 적응증별, 지역별 - 산업 예측(2025-2032년)
Non-Hodgkin Lymphoma Therapeutics Market Size, Share, and Growth Analysis, By Therapeutic Type, By Drug class, By Administration Route, By Indication, By Region - Industry Forecast 2025-2032
상품코드 : 1738068
리서치사 : SkyQuest Technology Consulting Pvt. Ltd.
발행일 : 2025년 05월
페이지 정보 : 영문 197 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,309,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,551,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 9,792,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

비호지킨림프종 치료제 세계 시장 규모는 2023년에 52억 달러로 평가되었으며, 예측 기간(2025-2032년) 동안 CAGR 6.9%로, 2024년 55억 6,000만 달러에서 2032년에는 94억 8,000만 달러로 성장할 전망입니다.

세계 비호지킨림프종(NHL) 치료제 시장은 고령화와 조기 발견을 가능하게 하는 진단 기술의 발전으로 인한 NHL 발병률 증가에 힘입어 크게 성장하고 있습니다. 이러한 환자 수의 증가는 효과적인 치료법에 대한 수요 증가로 이어져 제약회사와 의료 서비스 제공자들은 새로운 치료법 개발에 집중하고 있습니다. 또한, 연구개발에 대한 투자도 급증하여 시장 확대를 촉진하고 있습니다. 특히 암세포를 효과적으로 표적화하여 파괴하는 면역요법, 특히 키메라 항원 수용체(CAR) T 세포 치료의 발전은 주목할 만한 추세입니다. 이러한 혁신적인 치료법은 환자의 예후를 개선하고 맞춤형 요법으로의 전환을 촉진하여 비호지킨림프종 치료제 부문의 성장을 더욱 촉진하고 있습니다.

목차

소개

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

비호지킨림프종 치료제 시장 규모 : 치료 종류별 & CAGR(2025-2032년)

비호지킨림프종 치료제 시장 규모 : 약물 종류별 & CAGR(2025-2032년)

비호지킨림프종 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)

비호지킨림프종 치료제 시장 규모 : 적응증별 & CAGR(2025-2032년)

비호지킨림프종 치료제 시장 규모 : 지역별 & CAGR(2025-2032년)

경쟁 정보

주요 기업 개요

결론과 제안

ksm
영문 목차

영문목차

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 5.2 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 9.48 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing significant growth, driven by the rising incidence of NHL, primarily due to an aging population and advancements in diagnostic technologies that enable earlier detection. This increasing patient base is resulted in a higher demand for effective treatments, prompting pharmaceutical companies and healthcare providers to focus on developing new therapeutic options. Additionally, there is a surge in research and development investments, stimulating market expansion. A notable trend is the advancement of immunotherapy, particularly Chimeric Antigen Receptor (CAR) T-cell therapies, which effectively target and destroy cancer cells. These innovative treatments improve patient outcomes, fostering a shift toward personalized regimens and further fueling growth within the NHL therapeutics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Hodgkin Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Hodgkin Lymphoma Therapeutics Market Segments Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market is segmented by Therapeutic Type, Drug class, Administration Route, Indication and region. Based on Therapeutic Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy and Radiation Therapy. Based on Drug class, the market is segmented into Monoclonal Antibodies, Chemotherapeutic Agents, Bruton's Tyrosine Kinase Inhibitors and Immunomodulators. Based on Administration Route, the market is segmented into Intravenous, Oral and Subcutaneous. Based on Indication, the market is segmented into Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and Burkitt Lymphoma. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Hodgkin Lymphoma Therapeutics Market

The global non-Hodgkin lymphoma therapeutics market is primarily driven by the rising incidence of non-Hodgkin lymphoma, largely attributed to an aging population and various lifestyle factors. As the number of diagnoses continues to climb, there is an escalating need for advanced treatment solutions, including immunotherapies, chemotherapy, and targeted therapies. This heightened demand for innovative treatment options not only reflects the urgency in addressing patients' needs but also propels significant growth in the market, further encouraging research and development efforts aimed at improving patient outcomes and expanding therapeutic possibilities in combating this form of cancer.

Restraints in the Global Non-Hodgkin Lymphoma Therapeutics Market

The growth of the Global Non-Hodgkin Lymphoma Therapeutics market faces substantial obstacles, particularly in developing regions where there is a limited understanding of non-Hodgkin lymphoma. The challenges associated with early diagnosis significantly impede market progression, as insufficient healthcare infrastructure and lack of diagnostic resources create delays in identifying and treating the condition. This lack of timely intervention adversely impacts the demand for therapeutic options, ultimately constraining market expansion in these underserved areas. Addressing these awareness and infrastructure gaps is crucial for enabling better access to treatments and enhancing market potential in the long term.

Market Trends of the Global Non-Hodgkin Lymphoma Therapeutics Market

The Global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing a significant shift towards immunotherapy, particularly with the rise of CAR-T cell therapies. This innovative approach leverages the body's immune response to effectively target and eliminate lymphoma cells, showing remarkable efficacy in patients with relapsed or refractory cases. The increasing approval of these advanced therapies, coupled with ongoing research and clinical trials, underscores a growing acceptance and demand within the healthcare community. As a result, the market is projected to expand rapidly, driven by enhancements in treatment outcomes, patient quality of life, and the potential for personalized medicine strategies in NHL management.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Therapeutic Type & CAGR (2025-2032)

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Drug class & CAGR (2025-2032)

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Administration Route & CAGR (2025-2032)

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Indication & CAGR (2025-2032)

Global Non-Hodgkin Lymphoma Therapeutics Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기